Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kezar Life Sciences (KZR) EBT Margin (2021 - 2025)

Historic EBT Margin for Kezar Life Sciences (KZR) over the last 5 years, with Q2 2025 value amounting to 4537.75%.

  • Kezar Life Sciences' EBT Margin fell 8355700.0% to 4537.75% in Q2 2025 from the same period last year, while for Jun 2025 it was 10907.7%, marking a year-over-year increase of 124977700.0%. This contributed to the annual value of 1455.29% for FY2023, which is N/A changed from last year.
  • As of Q2 2025, Kezar Life Sciences' EBT Margin stood at 4537.75%, which was down 8355700.0% from 4771.18% recorded in Q1 2025.
  • Kezar Life Sciences' EBT Margin's 5-year high stood at 8938.36% during Q4 2021, with a 5-year trough of 330.04% in Q3 2023.
  • Its 5-year average for EBT Margin is 5327.83%, with a median of 5682.8% in 2022.
  • As far as peak fluctuations go, Kezar Life Sciences' EBT Margin skyrocketed by 3626600bps in 2023, and later tumbled by -9404500bps in 2024.
  • Quarter analysis of 5 years shows Kezar Life Sciences' EBT Margin stood at 8938.36% in 2021, then tumbled by -33bps to 5951.1% in 2022, then tumbled by -106bps to 330.04% in 2023, then surged by 1728bps to 5373.32% in 2024, then fell by -16bps to 4537.75% in 2025.
  • Its EBT Margin was 4537.75% in Q2 2025, compared to 4771.18% in Q1 2025 and 5373.32% in Q2 2024.